NRP2 and cancer: Because NRP2 expression is significantly associated with poor prognosis in renal cell carcinomas, colorectal carcinomas, gastric carcinomas, osteosarcoma, breast, pancreatic, and bladder cancer (7–13), it has become an attractive target for cancer therapy.